Modified Form 1449/PTO	Application Number	10/808,678
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	March 25, 2004
	First Named Inventor	Jeremy Green
	Group Art Unit	1625
	Examiner Name	Amelia A. Owens
	Attorney Docket Number	VPI/02-137 US

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date/Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S.P.T.O. MAY 18 2007 PATENT & TRADEMARK OFFICE

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	Translation No

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
/N.C./	C10	Heideman et al., "Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK_4," *J. Gene Medicine* 6: 317-327 (2004).
/N.C./	C11	Tomioka et al., "Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model," *Cancer Research* 61: 7518-7524 (2001).
/N.C./	C12	Saga et al., "Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival," *Gene Therapy* 8: 1450-1455 (2001).
/N.C./	C13	Martin et al., "Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist," *Carcinogenesis* 24(8): 1317-1323 (2003).
/N.C./	C14	Davies et al., "The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo," *Int. J. Cancer* 106:348-354 (2003).
/N.C./	C15	Christensen et al., "A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo," *Cancer Research* 63: 7345-7355 (2003).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Nizal Chandrakumar/	Date Considered	07/11/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

OIPE JC16 FEB 11 2005 PATENT & TRADEMARK OFFICE

Modified Form 1449/PTO	Application Number	10/808,678
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	March 25, 2004
	First Named Inventor	Jeremy Green
	Group Art Unit	1632
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/02-137 US

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
/N.C./	A1	5,733,920	Mar. 31, 1998	Mansuri et al.			

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
/N.C./	B1	WO	01/53266	Thrombogenix Pty Ltd.	26 July 2001		
/N.C./	B2	WO	98/17662	Novartis Ag	30 April 1998		

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
/N.C./	C1	Edwards et al., "Antineoplastic Activity and Cytotoxicity of Flavones, Isoflavones, and Flavanones", Abstract XP-009035912, J. of Natural Products, Pages 85-91, 1979.
/N.C./	C2	Database Chemabs, "Amino Acid Derivatives and Oximes of Flavones" Abstract XP-002295239, Chem. Of Heterocyclic Compounds, 2002.
/N.C./	C3	Database Chemabs, "Benzo-.gamma.-pyrones. Part XIV. Reaction of C-substituted 2-phenyl-4H-1-benzopyran-4-ones with hydroxylamine", Abstract XP-002295240, Polish J. of Chem., 1991.
/N.C./	C4	Sen et al., "Search for New Antimalarials. Part V. Synthesis of Some 8-aminoalkylamino- and 8-dialkylaminoalkylamino-chromones", Abstract XP-009035940, J. of the Indian Chem. Soc., Calcutta, Pages 217-222, 1960.
/N.C./	C5	Weng, Lingling, et al., Database Chemabs, "Preparation of Isoflavone Alicyclic Ethers and Oxime Derivatives", Abstact XP-002295241, Materia Medica Inst., Huaxi Med. College, Peop. Rep. China, 1993.
/N.C./	C6	Beugelmans et al., "Action of Hydroxylamine on Chromone and Khellin. Oxime vs. Isoxazoles Structures", XP-002295236, J. of Organic Chem., Vol. 42, No. 8, Pages 1356-1360, 1977.
/N.C./	C7	Database Chemab, "Thiazole Analogs of Isoflavones", Abstact XP-002295242, Khimichni ta Biologichni Nauki, 1980.
/N.C./	C8	Spatz et al., "7,2',4'-Trimethoxyflavone", J. of Organic Chem., Abstract XP-002295237, Vol. 24, No. 9, Pages 1381-1382, 1959.
/N.C./	C9	Eiden et al., "Uber die Reaktion Von Hydroxylamin Mit 2,6-Dimethyl-3-Acetylchromon", Tetrahedron Letters, Abstract XP-002295238, Vol. 17, Pages 1439-1442, 1970.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Nizal Chandrakumar/	Date Considered	07/11/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.